Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images

CONCLUSION: AI applied to baseline ECG images can stratify the risk of CTRCD associated with anthracycline or trastuzumab exposure.CONDENSED ABSTRACT: There is an unmet need for scalable and affordable biomarkers to stratify the risk of cancer therapeutics-related cardiac dysfunction (CTRCD). In this hospital system-based, decade-long cohort of patients without cardiomyopathy receiving anthracyclines or trastuzumab, a validated artificial intelligence algorithm applied to baseline electrocardiographic (AI-ECG) images identified individuals with a 2-fold and 4.8-fold risk of developing any cardiomyopathy or left ventricular ejection fraction <40%, respectively. This supports a role for AI-ECG interpretation of images as a scalable approach for the baseline risk stratification of patients initiating cardiotoxic chemotherapy.PMID:38562897 | PMC:PMC10984033 | DOI:10.1101/2024.03.12.24304047
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research